OSI Pharmaceuticals Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Melville NY United States (1983)
Status: Acquired by Astellas (2010) → now Leo Pharma (2015)

Organization Overview

First Clinical Trial
2001
NCT00085826
First Marketed Drug
2004
erlotinib (tarceva)
First NDA Approval
2004
erlotinib (tarceva)
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

OSI PHARMS